An observational study in Influenza With Pneumonia and Invasive Pulmonary Aspergillosis, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients in ICU.
This trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients in ICU, and correlate findings with occurrence of secondary invasive pulmonary aspergillosis infection.
All consecutive patients aged 18 or older admitted to ICU during the inclusion period with respiratory distress due to influenza positive/negative community acquired pneumonia (CAP) will be included.
43 studies on the registry are indexed under Invasive Pulmonary Aspergillosis; 9 are open to participants now.
This study's planned enrollment of 45 is below the median of 130 across 27 observational studies indexed under Invasive Pulmonary Aspergillosis.
Browse Invasive Pulmonary Aspergillosis studies →Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Critically ill community-acquired pneumonia patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All consecutive patients older than 18 years, admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza
Difference in immune cell profile in blood between influenza and non-influenza CAPIV patients at ICU.
Immunophenotyping of blood will be performed to determine number of neutrophils, T- and B-cell subsets, NK cell and myeloid cell subsets. Difference in influenza positive and influenza negative patients is expected.
Time frame: through study completion, after 3 influenza seasons (3 years)
Difference in cytokine production of mononuclear cells to fungal stimulation in blood between influenza and non-influenza CAPIV patients at ICU.
Key cytokine reaction of mononuclear cells (PBMC) after fungal stimulation will be performed. Difference in influenza positive and influenza negative patients is expected.
Time frame: through study completion, after 3 influenza seasons (3 years)
Difference in function of blood neutrophils between influenza and non-influenza CAPIV patients at ICU.
Functional analysis by killing assay will be performed.
Time frame: through study completion, after 3 influenza seasons (3 years)
Difference in in immune cell profile in BAL fluid between influenza and non-influenza CAPIV patients at ICU.
Immunophenotyping of BAL fluid will be performed to determine number of neutrophils, T- and B-cell subsets, NK cell and myeloid cell subsets. Difference in influenza positive and influenza negative patients is expected.
Time frame: through study completion, after 3 influenza seasons (3 years)
Difference in cytokine production of mononuclear cells to fungal stimulation in BAL fluid between influenza and non-influenza CAPIV patients at ICU.
Key cytokine reaction of mononuclear BAL fluid cells after fungal stimulation will be performed. Difference in influenza positive and influenza negative patients is expected.
Time frame: through study completion, after 3 influenza seasons (3 years)
Difference in function of BAL fluid neutrophils between influenza and non-influenza CAPIV patients at ICU.
Functional analysis by killing assay will be performed.
Time frame: through study completion, after 3 influenza seasons (3 years)
Difference in pathological hallmarks between influenza and non-influenza CAPIV patients at ICU.
Biopsies of respiratory tract tissue will be compared between two groups.
Time frame: through study completion, after 3 influenza seasons (3 years)
Difference in longitudinal alterations in phagocytic cell and mononuclear inflammatory cell subsets in blood and BAL fluid and their response to fungal stimulation between the main study arms.
Longitudinal alterations in advanced immunophenotyping results and (fungal) cell stimulation will be analysed and compared between groups.
Time frame: through study completion, after 3 influenza seasons (3 years)
Longitudinal differences in anatomopathological characteristics of the respiratory tract in CAPIV +/- influenza
Respiratory tract biopsies will be compared longitudinally throughout the disease course.
Time frame: through study completion, after 3 influenza seasons (3 years)
Correlation of findings with invasive pulmonary aspergillosis incidence
All data will be compared within each group between patients that develop IPA vs no development of IPA.
Time frame: through study completion, after 3 influenza seasons (3 years)
Correlation of findings with outcome
All data will be compared to outcome measures (length of ICU stay, mortality, etc) to find hallmarks of severe disease.
Time frame: through study completion, after 3 influenza seasons (3 years)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2019 (actual). Primary completion is estimated for Apr 2027, 99 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Invasive Pulmonary Aspergillosis →
Universitaire Ziekenhuizen KU Leuven →